Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT06539481
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin Institute of Health Department of Ophthalmology, Berlin, Germany
🇪🇸Fundación Jiménez Díaz, Madrid, Spain
🇩🇪Augenzentrum am St. Franziskus-Hospital Münster, Münster, Germany
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 125
- Registration Number
- NCT05322070
- Locations
- 🇺🇸
Retina Vitreous Associates, Toledo, Ohio, United States
🇺🇸Retina Consultants, Fargo, North Dakota, United States
🇺🇸Tennessee Retina, Nashville, Tennessee, United States
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT04469595
- Locations
- 🇺🇸
Investigative Site, Warrenton, Virginia, United States
A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2015-09-16
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT02472366
Phase 4 IOP Signals Associated With ILUVIEN®
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 153
- Registration Number
- NCT02424019
- Locations
- 🇺🇸
University of Maryland Eye Associates, Baltimore, Maryland, United States
🇺🇸The University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Sabates Eye Center Research Division, Leawood, Kansas, United States
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
- Conditions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT02080091
Iluvien Registry Safety Study
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 559
- Registration Number
- NCT01998412
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT01304706
Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT00770770
- Locations
- 🇺🇸
University of Kentucky Department of Ophthalmology, Lexington, Kentucky, United States
🇺🇸Cole Eye Institute, Cleveland, Ohio, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy
- Conditions
- Interventions
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Alimera Sciences
- Target Recruit Count
- 17
- Registration Number
- NCT00695318
- Locations
- 🇺🇸
Kresge Eye Institute, Detroit, Michigan, United States